摘要
JAK/STAT信号通路在皮肌炎发病中起着重要作用。JAK抑制剂能阻断依赖JAK/STAT通路相关因子的信号转导,抑制免疫细胞激活和T细胞介导的炎症性反应。目前美国食品药品监督管理局批准的JAK抑制剂适应证只有风湿性关节炎和骨髓纤维化,但已有不少应用JAK抑制剂治疗难治性皮肌炎的报道。本文综述JAK/STAT通路在皮肌炎发病机制中的作用、JAK抑制剂治疗皮肌炎的作用机制及临床应用。
The Janus kinase(JAK)/signal transducer and activator of transcription(STAT)signaling pathway plays an important role in the occurrence of dermatomyositis.JAK inhibitors can block signal transduction dependent on JAK/STAT pathway-related factors,and inhibit immune cell activation and T cell-mediated inflammatory responses.So far,the US Food and Drug Administration(FDA)has only approved rheumatic arthritis and myelofibrosis as the indications of JAK inhibitors,but there have been many reports on JAK inhibitors for the treatment of refractory dermatomyositis.This review summarizes the role of JAK/STAT pathway in the pathogenesis of dermatomyositis,the mechanism of action and clinical application of JAK inhibitors in the treatment of dermatomyositis.
作者
花玮玮
龚春燕
Hua Weiwei;Gong Chunyan(Department of Pharmacy,Hospital of Dermatology,Chinese Academy of Medical Sciences and Peking Union Medical College,Nanjing 210042,China)
出处
《中华皮肤科杂志》
CAS
CSCD
北大核心
2021年第3期264-267,共4页
Chinese Journal of Dermatology
